Form 8-K - Current report:
SEC Accession No. 0001104659-25-105594
Filing Date
2025-11-03
Accepted
2025-11-03 16:44:01
Documents
15
Period of Report
2025-11-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20251103x8k.htm   iXBRL 8-K 39724
2 EX-99.1 plx-20251103xex99d1.htm EX-99.1 29867
3 GRAPHIC plx-20251103xex99d1001.jpg GRAPHIC 10659
4 GRAPHIC plx-20251103xex99d1002.jpg GRAPHIC 5450
  Complete submission text file 0001104659-25-105594.txt   213442

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20251103.xsd EX-101.SCH 2891
6 EX-101.LAB plx-20251103_lab.xml EX-101.LAB 16013
7 EX-101.PRE plx-20251103_pre.xml EX-101.PRE 10758
17 EXTRACTED XBRL INSTANCE DOCUMENT plx-20251103x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 251444821
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)